

MEA Hereditary Cancer Testing Market - Industry Trends and Forecast to 2029

Market Report | 2022-10-01 | 176 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

Middle East and Africa hereditary cancer testing market is projected to register a CAGR of 11.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Middle East and Africa Hereditary Cancer Testing Market, By Test Type (Multi Panel Set, and Single-Site Genetic Test) Diagnosis Type (Biopsy, Imaging, Lab Tests) Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray) Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Vol-Hippel Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes) End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others) Distribution Channel (Direct Tender, Retail Sales) Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa) Industry Trends and Forecast to 2029

Some of the factors boosting the growth of the hereditary cancer testing market are:

- Rising incidence of hereditary cancer
- Increased demand for non-invasive testing methods

Market Players:

The key market players for Middle East and Africa hereditary cancer testing market are listed below:

- Invitae Corporation
- Illumina, Inc.
- Natera, Inc.
- CENTOGENE N.V.
- 4baseCare
- Biocartis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Fulgent Genetics
- Ambry Genetics
- BioReference
- PerkinElmer Inc.
- LifeLabs
- Abbott
- BIO-HELIX
- Cepheid
- Eurofins Scientific

Table of Contents:

TABLE OF CONTENTS

1 INTRODUCTION	31
1.1 OBJECTIVES OF THE STUDY	31
1.2 MARKET DEFINITION	31
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET	31
1.4 CURRENCY AND PRICING	33
1.5 LIMITATIONS	33
1.6 MARKETS COVERED	34
2 MARKET SEGMENTATION	37
2.1 MARKETS COVERED	37
2.2 GEOGRAPHICAL SCOPE	38
2.3 YEARS CONSIDERED FOR THE STUDY	39
2.4 DBMR TRIPOD DATA VALIDATION MODEL	40
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	43
2.6 MULTIVARIATE MODELLING	44
2.7 MARKET END USER COVERAGE GRID	45
2.8 SOURCE LIFELINE CURVE	46
2.9 DBMR MARKET POSITION GRID	47
2.10 VENDOR SHARE ANALYSIS	49
2.11 SECONDARY SOURCES	50
2.12 ASSUMPTIONS	50
3 EXECUTIVE SUMMARY	51
4 PREMIUM INSIGHT	54
4.1 PESTEL ANALYSIS	55
4.2 PORTER'S FIVE FORCES	56
5 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: REGULATIONS	57
6 MARKET OVERVIEW	62
6.1 DRIVERS	64
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER	64
6.1.2 INCREASE IN THE GERIATRIC POPULATION	64
6.1.3 RISING HEALTHCARE SPENDING	65
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING	65
6.2 RESTRAINTS	66

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.2.1 HIGH COST OF HEREDITARY CANCER TESTING	66
6.2.2 LACK OF SKILLED PROFESSIONALS	67
6.3 OPPORTUNITIES	67
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS	67
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS	68
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS	69
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES	69
6.4 CHALLENGES	70
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING	70
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS	71
7 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE	72
7.1 OVERVIEW	73
7.2 MULTI PANEL TEST	76
7.3 SINGLE-SITE GENETIC TEST	76
8 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE	77
8.1 OVERVIEW	78
8.2 BIOPSY	81
8.2.1 NEEDLE BIOPSIES	81
8.2.2 ENDOSCOPIC BIOPSIES	81
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY	82
8.2.4 LAPAROTOMY AND THORACOTOMY	82
8.2.5 OTHERS	82
8.3 IMAGING	82
8.3.1 MAGNETIC RESONANCE IMAGING (MRI)	83
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN	83
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN	83
8.3.4 NUCLEAR SCAN	83
8.3.5 ULTRASOUND	83
8.3.6 X-RAYS	83
8.4 LAB TESTS	84
8.4.1 BLOOD	84
8.4.2 URINE	84
8.4.3 OTHERS	84
9 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY	85
9.1 OVERVIEW	86
9.2 POLYMERASE CHAIN REACTION (PCR)	89
9.3 SEQUENCING	89
9.4 MICRO ARRAY	90
10 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE	91
10.1 OVERVIEW	92
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME	95
10.3 COWDEN SYNDROME	95
10.4 LYNCH SYNDROME	96
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME	96
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)	97
10.7 LI-FRAUMENI SYNDROME	97
10.8 VON HIPPEL-LINDAU DISEASE	98

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME	98
11 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER	99
11.1 OVERVIEW	100
11.2 HOSPITALS	103
11.3 CLINICS	103
11.4 DIAGNOSTIC CENTERS	104
11.5 RADIOLOGY CENTERS	104
11.6 LABORATORIES	105
11.7 OTHERS	105
12 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL	106
12.1 OVERVIEW	107
12.2 DIRECT TENDER	110
12.3 RETAIL SALES	110
13 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY REGION	111
13.1 MIDDLE EAST AND AFRICA	112
13.1.1 SOUTH AFRICA	120
13.1.2 SAUDI ARABIA	124
13.1.3 U.A.E.	128
13.1.4 EGYPT	132
13.1.5 ISRAEL	136
13.1.6 REST OF THE MIDDLE EAST AND AFRICA	140
14 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE	141
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA	141
15 SWOT ANALYSIS	142
16 COMPANY PROFILE	143
16.1 ABBOTT	143
16.1.1 COMPANY SNAPSHOT	143
16.1.2 REVENUE ANALYSIS	143
16.1.3 COMPANY SHARE ANALYSIS	144
16.1.4 PRODUCT PORTFOLIO	144
16.1.5 RECENT DEVELOPMENTS	144
16.2 ILLUMINA, INC. (2021)	145
16.2.1 COMPANY SNAPSHOT	145
16.2.2 REVENUE ANALYSIS	145
16.2.3 COMPANY SHARE ANALYSIS	146
16.2.4 PRODUCT PORTFOLIO	146
16.2.5 RECENT DEVELOPMENTS	147
16.3 PERKINELMER INC. (2021)	148
16.3.1 COMPANY SNAPSHOT	148
16.3.2 REVENUE ANALYSIS	148
16.3.3 COMPANY SHARE ANALYSIS	149
16.3.4 PRODUCT PORTFOLIO	149
16.3.5 RECENT DEVELOPMENTS	149
16.4 LIFELABS GENETICS	150
16.4.1 COMPANY SNAPSHOT	150
16.4.2 COMPANY SHARE ANALYSIS	150
16.4.3 PRODUCT PORTFOLIO	151

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.4.4 RECENT DEVELOPMENTS	151
16.5 EUROFINS SCIENTIFIC (2021)	152
16.5.1 COMPANY SNAPSHOT	152
16.5.2 REVENUE ANALYSIS	152
16.5.3 COMPANY SHARE ANALYSIS	153
16.5.4 PRODUCT PORTFOLIO	153
16.5.5 RECENT DEVELOPMENT	153
16.6 AMBRY GENETICS	154
16.6.1 COMPANY SNAPSHOT	154
16.6.2 REVENUE ANALYSIS	154
16.6.3 PRODUCT PORTFOLIO	155
16.6.4 RECENT DEVELOPMENTS	155
16.7 BIOCARDIS	156
16.7.1 COMPANY SNAPSHOT	156
16.7.2 REVENUE ANALYSIS	156
16.7.3 PRODUCT PORTFOLIO	157
16.7.4 RECENT DEVELOPMENTS	157
16.8 BIO-HELIX	158
16.8.1 COMPANY SNAPSHOT	158
16.8.2 PRODUCT PORTFOLIO	158
16.8.3 RECENT DEVELOPMENTS	158
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)	159
16.9.1 COMPANY SNAPSHOT	159
16.9.2 REVENUE ANALYSIS	159
16.9.3 PRODUCT PORTFOLIO	160
16.9.4 RECENT DEVELOPMENT	160
16.10 CENTOGENE N.V. (2021)	161
16.10.1 COMPANY SNAPSHOT	161
16.10.2 REVENUE ANALYSIS	161
16.10.3 PRODUCT PORTFOLIO	162
16.10.4 RECENT DEVELOPMENT	162
16.11 CEPHEID	163
16.11.1 COMPANY SNAPSHOT	163
16.11.2 PRODUCT PORTFOLIO	163
16.11.3 RECENT DEVELOPMENT	163
16.12 FULGENT GENETICS	164
16.12.1 COMPANY SNAPSHOT	164
16.12.2 REVENUE ANALYSIS	164
16.12.3 PRODUCT PORTFOLIO	165
16.12.4 RECENT DEVELOPMENT	165
16.13 INVITAE CORPORATION	166
16.13.1 COMPANY SNAPSHOT	166
16.13.2 REVENUE ANALYSIS	166
16.13.3 PRODUCT PORTFOLIO	167
16.13.4 RECENT DEVELOPMENT	167
16.14 NATERA, INC. (2021)	168
16.14.1 COMPANY SNAPSHOT	168

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.14.2 REVENUE ANALYSIS	168
16.14.3 PRODUCT PORTFOLIO	169
16.14.4 RECENT DEVELOPMENTS	169
16.15 4BASECARE.	171
16.15.1 COMPANY SNAPSHOT	171
16.15.2 PRODUCT PORTFOLIO	171
16.15.3 RECENT DEVELOPMENTS	172
17 QUESTIONNAIRE	173
18 RELATED REPORTS	176

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MEA Hereditary Cancer Testing Market - Industry Trends and Forecast to 2029

Market Report | 2022-10-01 | 176 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com